相关实验视频
Updated: Jun 26, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
专注于Filgotinib在类风湿性关节炎中:基于试验的审查
Elpida Skouvaklidou1, Dimitrios Deligeorgakis1, Anastasia Skalkou1
1Department of Rheumatology, 4th Department of Internal Medicine, Hippokration Hospital, Thessaloniki, Greece.
Mediterranean journal of rheumatology
|May 17, 2024
概括
菲尔戈提尼布是一种JAK1抑制剂,在类风湿性关节炎 (RA) 和性结肠炎中表现出持续的疗效,改善了疾病活性和生活质量. 虽然它通常是安全的,但它带有感染的风险增加,不包括疹.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学 是一个学科.
背景情况:
- 简氏激酶 (JAK) /信号转换器和转录激活器 (STAT) 途径在各种类风湿性疾病的发展中起着至关重要的作用.
- 雅克抑制剂为类风湿性关节炎 (RA) 提供有效的治疗选择,提供持续的治疗效益.
- 菲尔戈提尼布是一种选择性JAK1抑制剂,已被批准用于RA和性结肠炎,扩大治疗选择.
研究的目的:
- 分析filgotinib在患有类风湿性关节炎的患者中的疗效.
- 审查与菲尔戈提尼布治疗相关的特定药物安全警告.
- 评估filgotinib在不同患者群体中的性能,以及与其他治疗方法的对比.
主要方法:
- 对涉及RA患者的随机临床试验的综述,包括那些以前没有接受过治疗的,有csDMARD经验的或bDMARD经验的患者.
- 与安慰剂,甲铁和阿达利姆巴相比,对菲尔戈蒂尼布的疗效的分析.
- 包括长期扩展试验的数据,长达四年的连续filgotinib管理.
主要成果:
- 菲尔戈提尼布在改善中度至重度RA的疾病活动参数和生活质量方面表现出纵向有效性.
- 在一对一的比较中,发现菲尔戈提尼布200毫克的效果与阿达利穆马布不逊色.
- 一个值得注意的安全警告包括感染性不良反应的风险增加,疹感染的发病率很低.
结论:
- 菲尔戈提尼布对中度至重度的RA患者提供持续的疗效,影响疾病活动和生活质量.
- 药物的安全性概况表明感染风险较高,尽管疹发病率较低.
- 菲尔戈提尼布在JAK抑制剂类中代表了一种有价值的治疗选择,用于管理RA.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126

